We examined the completeness of TNM staging of small-cell (SCLC) and nonsmall-cell (NSCLC) lung cancer in the national Danish Cancer Registry (DCR) and whether staging varied by year of diagnosis, gender, age, degree of comorbidity, or presence of histopathological diagnosis.
Introduction
Lung cancer is one of the most common malignancies and is the leading cause of cancer-related death in Denmark, as well as worldwide. [1] [2] [3] In Denmark, incidence rates of lung cancer in 2009 were 83 (men) and 64 (women) per 100,000 person-years. Lung cancer is classified into two subtypes, including small cell (SCLC, 15%-18% of incident cases) and non-small cell lung cancer (NSCLC, 82%-85% of incident cases) based on histopathology and differences in prognosis and treatment. Stages of SCLC (limited and extensive) and NSCLC (I-IV) are assigned according to TNM classification, which addresses tumor size and growth into neighboring organs (T), lymph node involvement (N), and distant metastases (M). Prognosis and treatment choices vary according to cancer stage, but prognosis is also affected by age and level of comorbidity. [4] [5] [6] [7] [8] The five-year survival rate for SCLC patients is approximately 20% for limited disease and 0% for extensive disease. 9 Corresponding rates for NSCLC patients are 50% and approximately 5% for stage IA and IV, respectively. 10, 11 Only two studies Dovepress submit your manuscript | www.dovepress.com Completeness of TNM staging in the DCR is unknown. We therefore studied TNM completeness of SCLC and NSCLC, as well as conducted stratified analyses by year of diagnosis, gender, age, and level of comorbidity. Additionally, we suggest a method for defining stage categories in the presence of specific missing T, N, or M components.
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Material and methods
We performed this study in Denmark, which has a population of approximately 5.4 million. All residents are provided with tax-supported medical care which is free of charge. Since 1968, the Danish Civil Registration System has assigned a unique 10-digit personal identification number to all Danish residents. 17 This number is used in all Danish registers and allows unambiguous individual-level data linkage.
Identification and categorization of lung cancer patients
We identified all patients with a first-time lung cancer diagnosis (ICD-10 code C33-C34) recorded between January 1, 2004 
Comorbidity
We obtained data regarding comorbidity from the Danish National Patient Register (DNPR). 19 This register contains data regarding all admissions to non-psychiatric hospitals in Denmark since 1978 and outpatient settings since 1995. The data includes dates of admission/contact, discharge, and diagnosis codes according to the ICD-10. The presence of comorbidity was defined according to the Charlson Comorbidity Index 20, 21 (CCI), and categorized as low (CCI = 0), medium (CCI = 1-2), or high (CCI . 2) level of comorbidity. The CCI was based on all hospital diagnoses recorded in the DNPR within 10 years preceding the date of cancer diagnosis.
Statistical analysis
We computed completeness and corresponding 95% confidence intervals (CI) for the TNM registration overall and for each component (ie, T, N, and M). Completeness was defined as the number of individuals with TNM recordings divided by the total number of patients. We stratified completeness according to year of cancer diagnosis, gender, age at diagnosis (0-39 years, 40-59 years, 60-79 years, or $80 years), and level of comorbidity. We computed completeness separately for SCLC and NSCLC and, for NSCLC, for histologically verified disease. SCLC diagnosis had been verified histologically. We repeated the analyses using the algorithm for stage assignment in the presence of specific missing T, N, or M values. Analyses were performed using SAS (v 9.2; SAS Institute, Inc, Cary, NC, USA).
Results
We identified 24,734 patients (50% males) that had lung cancer in Denmark between 2004 and 2009. Of these, 3,658 (15%) had SCLC (Table 1 ) and 21,076 (85%) had NSCLC ( Table 2 ). Among those with NSCLC, 17,972 (85%) cases had been histologically verified. Median age at diagnosis was 69 years for all patients combined. The proportion of patients with preexisting hospital recorded comorbidity was similar between the two patient categories (47% among patients with SCLC, 50% among patients with NSCLC). Completeness also decreased with comorbidity level. The proportions of complete TNM staging were 81%, 76%, and 69% for low, medium, and high levels of comorbidity among patients with SCLC. The corresponding proportions were 81%, 76%, and 70% for patients with NSCLC.
Finally, we evaluated stage completeness for SCLC and NSCLC, allowing for the inclusion of missing TNM components as described above. When using this algorithm, overall stage completeness was 93.1% for SCLC and 91.1% for NSCLC. However, variations in completeness according to gender, age, year of diagnosis, and comorbidity showed a pattern similar to that of the original data (Tables 3 and 4 ).
Discussion
We found that the completeness of TNM staging for SCLC and NSCLC in the DCR was lower for elderly patients and/or those with severe comorbidity. Completeness increased during the study period (2004-2009) and did not vary by lung cancer subtype or gender. Among patients with NSCLC, completeness was higher for patients with a histologically verified diagnosis than for those without such diagnosis.
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Some SCLC as NSCLC cases without morphological information may have been misclassified. However, this potential misclassification likely had minor impact on the results, since we observed nearly the same completeness for SCLC as for NSCLC.
Completeness of lung cancer staging in the National Cancer Institute's (US) Surveillance, Epidemiology, and End Results (SEER) Program 12 and completeness of the Swedish Cancer Register 13 are higher than that of the DCR. Institutions participating in the SEER are financially rewarded, and SEER promotes education and conducts regular audits for cancer registration, 22 which may explain this higher completeness. However, neither report presented overall estimates nor information regarding which components of TNM were missing or the impact of cancer type (SCLC or NSCLC), diagnosis year, or comorbidity on the likelihood of proper TNM staging.
Our findings are consistent with those of previous studies examining unstaged malignant disease which showed that fragile, elderly and/or those requiring nursing care are more likely to have unstaged disease. 13, 23, 24 This is the first study to present TNM staging according to comorbidity levels.
In conclusion, overall completeness of the TNM registration of SCLC and NSCLC in the DCR is high, and the amount of incomplete data is likely to have a minor impact on studies examining prognosis or surveillance that rely on DCR data, particularly when evaluating potential sources of bias such as age and level of comorbidity. We further showed that overall stage completeness can be increased by including patients for which the TNM components provide unambiguous prognostic information, despite missing or misclassified information of individual staging components. Completeness of both SCLC and NSCLC registration decreased with increasing age and comorbidity level, but was not affected by gender or lung cancer subtype. Future studies examining treatment, prognosis, or screening policies that rely on TNM data from the DCR should be conducted to address these potential sources of bias. 
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